Diabetes

Your daily dose of the clinical news you may have missed.

Medha Munshi, MD, and James Bailey, III, MD, FACE, ECNU, discuss older adult patient cases and review their respective treatment approaches, sharing final takeaways to provide practical insights for managing diabetes in this patient population.

Medical experts discuss the importance of optimizing medication regimens for older patients with diabetes, emphasizing the need to keep treatment plans simple and highlight the value of continuous glucose monitors in monitoring patients and adjusting therapies accordingly.

Key opinion leaders in the management of diabetes discuss the process of deprescribing, or the process of medication simplification to encourage adherence and ease of regimens in older adult populations with type 2 diabetes.

Drs Medha Munshi and James Bailey offer insights into navigating the type 2 diabetes treatment landscape. They emphasize the importance of prioritizing cardiovascular and renal outcomes when selecting treatments for older adult populations.

Medha Munshi, MD, and James Bailey, III, MD, FACE, ECNU, discuss the current treatment landscape for type 2 diabetes, and highlight key considerations for the selection of first-line treatments for older adults with this condition.

Key opinion leaders in the management of diabetes define and discuss the impact and complexities of geriatric syndromes in older adults with T2D. They shed light on challenges like cognitive impairment, urinary incontinence, and neuropathy, offering insights into effective diabetes management strategies for this demographic.

Drs Medha Munshi and James Bailey discuss the definition of older adult patients, considering both chronological age and mental and physical state. They underscore the significance of customizing diabetes treatment to accommodate individual patient abilities, rather than solely basing decisions on age

Medha Munshi, MD, and James Bailey, III, MD, FACE, ECNU, delve into the management and burden of type 2 diabetes (T2D). They shed light on the prevalence of the disease in older adults and its potential health impacts as patients age, while also addressing risk factors and considerations for younger patients as they progress in age.

Your daily dose of the clinical news you may have missed.

DDW 24. New research shows patients with MASLD and T2D who used GLP-1 agonists had a reduced risk of progression to cirrhosis and HCC vs non-users.

Men with diabetes had a greater risk of CVD, lower limb and kidney complications, and diabetic retinopathy compared to women with diabetes.

In the phase 1b trial, treatment with once-weekly subcutaneous CT-388 led to a statistically significant mean placebo-adjusted weight loss of nearly 20%.

Your daily dose of the clinical news you may have missed.

Safety and HbA1c reduction with efsitora alfa dosed once weekly was comparable to both daily insulin degludec and daily insulin glargine, announced Lilly.

There have been 224 reported injuries as of April 15, 2024, the CDC said, but no reports of death related to the app intermittently crashing and rebooting.

Results also showed that older adults, men, and Black adults face an increased risk of advanced stages of CKM syndrome.

Diagnoses of diabetes increased the most in South Dakota between 2018 and 2021 at 18.45%; diagnoses decreased the most in Hawaii at 15.61%. More, here.

Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.

Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.

The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.

Your daily dose of the clinical news you may have missed.

Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.

Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.

Your daily dose of the clinical news you may have missed.